Articles related to MEDICAL MEETINGS AND EVENTS

The phase 3 EXTENTORCH trial has demonstrated the potential of toripalimab plus chemotherapy as a new standard first-line therapy for ES-SCLC, with a median progression-free survival of 5.8 months.

The ESMO Congress 2023 has highlighted how international studies in NSCLC are currently being reported at a rapid pace. This underscores the importance of staying updated on these advancements to provide optimal patient care.

Gain actionable insights into the diagnosis and management of nonmalignant blood disorders at Mayo Clinic’s Classical Hematology 2023 conference. Elevate your practice with evidence-based strategies from leading experts.

Learn about the evolving landscape of integrative oncology, where new guidelines and patient demand are pushing the field forward, yet skepticism about evidence-based practice remains.

Delve into key insights from ASCO 2023, which emphasized patient-centered care in genitourinary oncology, including the efficacy of virtual prostate cancer clinics and the critical need for initiating serious-illness conversations.

The ASCO 2023 meeting has unveiled key studies in prostate cancer, including insights into PSA levels post-radiation therapy, the role of BRCA mutations, and promising combination therapies.